Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated recombinant consensus interferon variant
- Development stage
- Phase 3
- Lead developer
- Chongqing Fujin Biological Medicine
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegylated recombinant consensus interferon variant is a long-acting Type I interferon developed by Chongqing Fujin Biopharmaceutical for the treatment of chronic hepatitis C. It consists of a consensus interferon (interferon alfacon-1) sequence—a synthetic protein designed to represent the most common amino acids across various natural alpha interferon subtypes—conjugated to a polyethylene glycol (PEG) moiety. This pegylation enhances the pharmacokinetic profile by reducing renal clearance and protecting the protein from enzymatic degradation, allowing for weekly subcutaneous administration. The drug binds to the heterodimeric Type I interferon receptor (IFNAR1 and IFNAR2), activating the JAK-STAT signaling pathway. This leads to the transcription of interferon-stimulated genes that exert potent antiviral, antiproliferative, and immunomodulatory effects, effectively inhibiting the replication of the hepatitis C virus (HCV).
- Other names
- Pegylated Recombinant Consensus Interferon Variant InjectionY-shape pegylated recombinant consensus interferon聚乙二醇重组集成干扰素变体
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on pegylated recombinant consensus interferon variant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated recombinant consensus interferon variant.